Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Settles With Spitzer; Trial Registry Will Focus On Phase III-IV

Executive Summary

Forest Labs' settlement agreement with New York Attorney General Eliot Spitzer requires less disclosure of clinical data than an earlier settlement between Spitzer and GlaxoSmithKline

You may also be interested in...



Negative Antidepressant Trial Results See Low Publication Rate, Study Finds

The vast majority of antidepressant clinical trials viewed by FDA as having negative or questionable results are either not published in medical journals or published in a way that conveys a positive outcome, according to results of a study published in the January 17 issue of the New England Journal of Medicine

Negative Antidepressant Trial Results See Low Publication Rate, Study Finds

The vast majority of antidepressant clinical trials viewed by FDA as having negative or questionable results are either not published in medical journals or published in a way that conveys a positive outcome, according to results of a study published in the January 17 issue of the New England Journal of Medicine

Access To Vaccine Safety Data Is Different Than Trial Databases, NVAC Says

The Institute of Medicine's proposal to open the Vaccine Safety Database to independent research is "very different" than granting public access to registries of clinical trials, the National Vaccines Advisory Committee said

Related Content

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel